{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:23:09Z","timestamp":1760300589454,"version":"3.40.5"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical Affairs, Upjohn, Pfizer Japan Inc.","award":["A6141128"],"award-info":[{"award-number":["A6141128"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>This study aimed to collect data on \u201ctriple therapy\u201d for heart failure (HF) with angiotensin-converting enzyme inhibitors (or receptor blockers), \u03b2-blockers, and mineralocorticoid receptor antagonists in all eight regions of Japan and clarify the reason for the selection of this therapeutic approach.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods and results<\/jats:title>\n<jats:p>We used data from April 2017 to March 2018 from the Medical Data Vision database (380 facilities) to analyze factors impacting triple therapy for HF. Among patients who were hospitalized for HF during the study period, 51,933 patients met the inclusion criteria and underwent further analyses. A reference value of 20.45% from Kanto was used to compare the eight Japanese regions.<\/jats:p>\n<jats:p>From the patient cohort, 10,006 (19.27%) patients receiving triple therapy were identified.<\/jats:p>\n<jats:p>The highest and lowest rates of triple therapy were in Chugoku (21.90%) and Shikoku (14.27%), respectively, suggesting regional differences in the use of triple therapy at discharge for patients with HF (P &lt; 0.001). Regression analysis revealed a decrease in the administration of triple therapy for patients with chronic kidney disease (odds ratio [OR], 0.45; 95% confidence interval [CI], 0.43\u20130.48]; P &lt; 0.001), those aged 75 years and older (OR, 0.46, 95% CI: 0.44\u20130.49; P &lt; 0.001), those from Shikoku (OR, 0.69; 95% CI, 0.60\u20130.80; P &lt; 0.001), those with chronic obstructive pulmonary disease (OR, 0.75; 95% CI, 0.68\u20130.84; P &lt; 0.001), those with anemia (OR, 0.78; 95% CI, 0.62\u20130.98; P = 0.034), and those from Tohoku (OR, 0.83; 95% CI, 0.75\u20130.92; P &lt; 0.001).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Future efforts to rectify the regional variance in drug therapy conforming to the guidelines for the treatment of acute and chronic HF will help to extend the healthy lifespans of patients with HF. Further clarification is required to determine instances where triple therapy should be avoided based on patient factors, and appropriate countermeasures should be identified.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0249711","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T17:37:36Z","timestamp":1619545056000},"page":"e0249711","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Actual state of \u201ctriple therapy\u201d for heart failure patients in eight regions of Japan: An analysis of a nationwide medical claims database"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6160-7223","authenticated-orcid":true,"given":"Daisuke","family":"Abe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Inomata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"issue":"10","key":"pone.0249711.ref001","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","article-title":"JCS 2017\/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure\u2014Digest Version","volume":"83","author":"Japanese Circulation Society, Japanese Heart Failure Society","year":"2019","journal-title":"Circ J"},{"issue":"4","key":"pone.0249711.ref002","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cardfail.2017.01.004","article-title":"Understanding the epidemiology of heart failure to improve management practices: an Asia-Pacific perspective","volume":"23","author":"J Rajadurai","year":"2017","journal-title":"J Card Fail"},{"key":"pone.0249711.ref003","unstructured":"Ministry of Health, Labour, and Welfare. 2016 Demographics Survey (determined numbers), overview. Japanese Ministry of Health, Labour, and Welfare, 2018 n.d. Available: https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/jinkou\/kakutei16\/index.html Accessed 30 October 2019."},{"key":"pone.0249711.ref004","unstructured":"Law No. 105. Basic law regarding measures against stroke, heart disease, and other cardiovascular diseases in order to lengthen of healthy life expectancy, 2018 n.d. Available: https:\/\/houseikyoku.sangiin.go.jp\/bill\/pdf\/h30-105.pdf. Accessed 30 October 2019."},{"issue":"21","key":"pone.0249711.ref005","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/CIRCULATIONAHA.104.500546","article-title":"Mechanisms and models in heart failure: the biomechanical model and beyond","volume":"111","author":"DL Mann","year":"2005","journal-title":"Circulation"},{"issue":"23","key":"pone.0249711.ref006","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0249711.ref007","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"issue":"9215","key":"pone.0249711.ref008","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"B Pitt","year":"2000","journal-title":"Lancet"},{"issue":"9386","key":"pone.0249711.ref009","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"CB Granger","year":"2003","journal-title":"Lancet"},{"issue":"21","key":"pone.0249711.ref010","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group","volume":"334","author":"M Packer","year":"1996","journal-title":"N Engl J Med"},{"issue":"22","key":"pone.0249711.ref011","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"M Packer","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"pone.0249711.ref012","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"B Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0249711.ref013","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"F Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"16","key":"pone.0249711.ref014","first-page":"e240","article-title":"American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"WRITING COMMITTEE MEMBERS","year":"2013","journal-title":"Circulation"},{"issue":"27","key":"pone.0249711.ref015","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"P Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"issue":"6","key":"pone.0249711.ref016","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1007\/s11936-008-0044-7","article-title":"Treatment of patients with heart failure and preserved ejection fraction","volume":"10","author":"A Deswal","year":"2008","journal-title":"Curr Treat Options Cardiovasc Med"},{"issue":"11","key":"pone.0249711.ref017","first-page":"2327","article-title":"The current status of cardiovascular medicine in Japan\u2014analysis of a large number of health records from a nationwide claim-based database, JROAD-DPC","volume":"80","author":"S Yasuda","year":"2016","journal-title":"Circ J Off J Jpn Circ Soc"},{"key":"pone.0249711.ref018","unstructured":"Ministry of Health, Labour, and Welfare. Statistical classifications of illnesses, injuries and causes of death, 2015 ed. n.d. Available: https:\/\/www.mhlw.go.jp\/toukei\/sippei\/. Accessed 30 October 2019."},{"key":"pone.0249711.ref019","unstructured":"Guideline Committee of the Japanese Heart Failure Society. Statement on the treatment of elderly patients with heart failure, 2016. n.d. Available: http:\/\/www.asas.or.jp\/jhfs\/pdf\/Statement_HeartFailurel.pdf Accessed 30 October 2019."},{"key":"pone.0249711.ref020","unstructured":"Circulatory disease measure promotion master plan in Japan. https:\/\/www.mhlw.go.jp\/stf\/newpage_14459.html Accessed 5 December 2020."},{"key":"pone.0249711.ref021","article-title":"Appropriateness rating for the application of optimal medical therapy and multidisciplinary care among heart failure patients","author":"S Shoji","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"9744","key":"pone.0249711.ref022","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"M B\u00f6hm","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"pone.0249711.ref023","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"JJV McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"pone.0249711.ref024","first-page":"7","article-title":"Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil","author":"E Kaplinsky","year":"2018","journal-title":"Drugs Context"},{"issue":"22","key":"pone.0249711.ref025","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"ET Kato","year":"2019","journal-title":"Circulation"},{"issue":"10","key":"pone.0249711.ref026","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1253\/circj.CJ-09-0254","article-title":"Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)","volume":"73","author":"M Tsuchihashi-Makaya","year":"2009","journal-title":"Circ J"},{"key":"pone.0249711.ref027","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12872-015-0127-9","article-title":"Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database","volume":"15","author":"H Aizawa","year":"2015","journal-title":"BMC Cardiovasc Disord"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0249711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T17:38:16Z","timestamp":1619545096000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0249711"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Shimosawa","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0249711","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,4,27]]}}}